Regeneron的业务发展 - Regeneron自2022年夏季以来取得了显著进展，公司回归增长，EV/营收倍数达到预期范围[1] - Regeneron的Libtayo产品在全球销售增长44%，接近年销售额达10亿美元的速度[16] - Regeneron的商业业务状况良好，继续保持增长，主要受益于Dupixent和Libtayo的强劲增长，以及新适应症和新产品的批准和推出[20] Regeneron的新药研发 - Regeneron计划进行第二阶段试验，测试两种抗体与semaglutide的组合效果，以及与semaglutide和安替巴的比较结果[9]

财务数据和关键指标变化 - 第四季度2023年总收入增长14%至34亿美元,主要由于Dupixent销售增长、EYLEA HD的推出以及Libtayo销售强劲 [66] - 第四季度2023年稀释每股净收益为11.86美元,净收益为14亿美元 [66] - 2023年全年公司自由现金流为39亿美元,截至2023年12月31日现金及可流动性证券余额为135亿美元 [74] 各条业务线数据和关键指标变化 Retinal业务 - 第四季度EYLEA HD和EYLEA合计美国净销售额为14.6亿美元,EYLEA HD首个完整季度净销售额为1.23亿美元 [51] - EYLEA HD和EYLEA合计占抗VEGF类药物市场份额49% [52] - 2024年4月1日EYLEA HD将获得永久性J码,有利于提高医生的开具信心 [54] Dupixent业务 - 第四季度全球Dupixent净销售额增长31%至32亿美元,美国净销售额增长28%至25亿美元 [56] - Dupixent在所有5个适应症领域均占据新开药物处方份额领先地位 [57] - 2023年Dupixent全球销售额达116亿美元,增长34% [14] Libtayo业务 - 第四季度全球Libtayo净销售额增长43%至2.44亿美元,美国净销售额为1.55亿美元 [63] - 预计2024年Libtayo销售有望超过10亿美元 [64] 各个市场数据和关键指标变化 - 抗VEGF药物市场整体增长健康,但存在季度和年度间的波动 [103] - 公司正在密切关注EYLEA HD和EYLEA在市场份额和定价方面的动态变化 [109] 公司战略和发展方向及行业竞争 - 公司2023年的5大战略重点包括:获批并成功推出EYLEA HD、捍卫EYLEA知识产权、推动Dupixent在新适应症的增长、推进肿瘤业务发展、推进早期管线 [12][13][14][15][16][17] - 2024年公司的战略重点包括:推动EYLEA HD的商业执行、继续推动Dupixent在现有适应症的增长以及在COPD适应症的潜在上市、推进肿瘤生物特异性药物odronextamab和linvoseltamab的上市 [18][19][20] - 公司正在积极布局肥胖和代谢疾病领域,包括开发结合GLP-1激动剂和肌肉保护抗体的创新疗法 [96][97][98][99] - 公司正在利用siRNA和CRISPR基因编辑技术开发治疗神经退行性疾病和遗传性疾病的创新疗法 [40][41][42][43][44][45] 管理层对经营环境和未来前景的评论 - 公司2023年取得了多项重大成就,为公司未来可持续增长和股东价值创造奠定了基础 [12] - 公司管理层对2024年的发展前景充满信心,认为公司有望在多个治疗领域实现重大进展 [12][18][19][20][21][22] 问答环节重要的提问和回答 问题1 **Tyler Van Buren 提问** 如何加快EYLEA HD患者从其他药物转换的速度? [89] **Marion McCourt 回答** EYLEA HD的临床数据、医生的使用体验、以及4月1日获得永久性J码将有助于加快转换速度 [90][91][92] 问题2 **George Yancopoulos 回答** 公司在肌肉保护抗体和GLP-1激动剂组合疗法方面的优势在于:1)发现并拥有单独针对两个关键调节因子myostatin和activin A的抗体;2)可以单独或联合评估这两种抗体,以获得最佳的疗效和安全性;3)正在开发一种单分子的GLP-1激动剂和肌肉保护抗体的融合蛋白,提供最佳的疗效和给药方便性 [96][97][98][99] 问题3 **George Yancopoulos 回答** 公司正在开发一种全新的治疗严重食物过敏的方法,利用BCMAxCD3双特异性干预联合Dupixent治疗。这种方法有望通过首先消除产生IgE的长寿浆细胞,然后阻断IgE的新生成,从而逆转严重过敏反应 [29]

Regeneron (REGN) reported $3.43 billion in revenue for the quarter ended December 2023, representing a year-over-year increase of 0.6%. EPS of $11.86 for the same period compares to $12.56 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $3.26 billion, representing a surprise of +5.37%. The company delivered an EPS surprise of +13.71%, with the consensus EPS estimate being $10.43.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- an ...

Regeneron Corporate Presentation F E B R U A R Y 2 0 2 4 This non-promotional presentation contains investigational data as well as forward-looking statements; actual results may vary materially. Note regarding forward-looking statements and non-GAAP financial measures Thispresentationincludesforward-lookingstatementsthatinvolverisksanduncertaintiesrelatingtofutureeventsandthefutureperformanceofRegeneronPharmaceuticals,Inc.("Regeneron"orthe"Company"),andactual eventsorresultsmaydiffermateriallyfromtheseforw ...

财报表现 - Regeneron (REGN)在最新季度每股盈利为11.86美元，超过了Zacks Consensus预期的10.43美元[1] - 这一季度的盈利惊喜达到了13.71%。公司在过去四个季度中四次超过了市场预期的每股盈利[2] - Regeneron在2023年12月结束的季度实现了34.3亿美元的营收，超过了Zacks Consensus预期5.37%[3] 股价走势 - 公司股价的未来走势将主要取决于管理层在财报电话会议上的评论[4]

Fourth quarter 2023 revenues increased 1% to $3.43 billion versus fourth quarter 2022; excluding RonapreveTM(a)(b), revenues increased 14%Full year 2023 revenues increased 8% to $13.12 billion versus full year 2022; excluding Ronapreve(a), revenues increased 12%Fourth quarter 2023 Dupixent® global net sales (recorded by Sanofi) increased 31% to $3.22 billion versus fourth quarter 2022; full year 2023 Dupixent global net sales increased 33% to $11.59 billion versus 2022Fourth quarter 2023 U.S. net sales for ...

TARRYTOWN, N.Y., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for linvoseltamab to treat adult patients with relapsed/refractory (R/R) multiple myeloma (MM) who have progressed after at least three prior therapies. Linvoseltamab is an investigational bispecific antibody designed to bridge B-cell maturation antigen (BCMA) on multiple myeloma cells w ...

The upcoming report from Regeneron (REGN) is expected to reveal quarterly earnings of $10.48 per share, indicating a decline of 16.6% compared to the year-ago period. Analysts forecast revenues of $3.26 billion, representing a decrease of 4.7% year over year.The consensus EPS estimate for the quarter has undergone an upward revision of 0.7% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timefra ...

Regeneron Cell Medicines成立 - Regeneron Pharmaceuticals, Inc.宣布成立Regeneron Cell Medicines，通过与2seventy bio, Inc.达成协议，获得其研究中的新型免疫细胞疗法管线的全面开发和商业化权利[1] - Regeneron将收购2seventy bio的前期和临床阶段管线，并承担与这些项目相关的持续程序、基础设施和人员成本[2] - Regeneron Cell Medicines将探索与Regeneron专有抗体和双特异性抗体的结合，推进下一代细胞疗法[3]

Regeneron (REGN) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2023. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on February 2. ...